It has previously been shown that EphA2 influences NSCLC cell signaling and has an impact on their response or refractoriness to EGFR-TKI treatment as well as upon targeting tumor cell expressed VEGFR2 [25,26,27,28,30,31,32,33,34]. Here, EPHA2 is linked to neoplasm.